Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis

被引：69

作者：

Balamuth, Naomi J.

Nichols, Kim E.

Paessler, Michele

Teachey, David T. ^{[1
]}

机构：

[1] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat,Div Oncol, Philadelphia, PA 19104 USA

[2] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2007年 / 29卷 / 08期

关键词：

immunotherapy; Epstein Barr virus; rituximab; lymphohistiocytosis;

D O I：

10.1097/MPH.0b013e3180f61be3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hemophagocytic lymphohistiocytosis is a rare, life-threatening complication of Epstein Barr virus (EBV) infection. Current treatments are directed at reducing virus-induced immune dysregulation. Addition of agents that eliminate EBV-infected B cells may improve therapeutic efficacy. On the basis of the observations that the anti-CD-20 monoclonal antibody rituximab reduces disease burden in individuals with EBV-associated lymphoproliferative disorders, we treated a patient with severe EBV-hemophagocytic lymphohistiocytosis using a combination of rituximab and chemotherapy. This patient demonstrated a rapid clinical response and an 18-fold reduction in EBV viral load within 24 hours of receiving rituximab. He remains free of disease 8 months after completing treatment.

引用

页码：569 / 573

页数：5

共 22 条

[1]

AMBRUSO DR, 1980, CANCER, V45, P2516, DOI 10.1002/1097-0142(19800515)45:10<2516::AID-CNCR2820451008>3.0.CO

[2]

2-V

[3] Prolonged illness after infectious mononucleosis is associated with altered immunity but not with increased viral load [J].